期刊文献+

(R)-3-氨基哌啶的合成与应用进展 被引量:1

Progress in Preparation and Application of (R)-3-Aminopiperidine
下载PDF
导出
摘要 (R)-3-氨基哌啶是一种手性小分子化合物,可通过化学合成法、手性拆分法或生物转化法进行制备。作为一种重要的药物中间体,(R)-3-氨基哌啶已用于利拉利汀(Linagliptin)、苯甲酸阿格列汀(Alogliptin benzoate)和曲格列汀琥珀酸盐(Trelagliptin succinate)等多种对2型糖尿病有治疗功能的二肽基肽酶Ⅳ(DPP-Ⅳ)抑制剂的合成。 As a chiral small molecule,(R)-3-aminopiperidine can be prepared by chemical synthesis,chiral separation,or biotransformation.As an important pharmaceutical intermediate,(R)-3-aminopiperidine has been utilized in the synthesis of several dipeptidyl peptidase-Ⅳ(DPP-Ⅳ)inhibitors aiming for the type-2 diabetes,such as Linagliptin,alogliptin benzoate,and trelagliptin succinate,etc.
作者 汪艺宁 蔡照胜 孙国香 WANG Yining;CAI Zhaosheng;SUN Guoxiang(School of Chemistry & Chemical Engineering, Yancheng Institute of Technology, Yancheng , Jiangsu 224051 , China)
出处 《化学世界》 CAS CSCD 2018年第4期201-207,共7页 Chemical World
基金 江苏省产学研前瞻性(No.BY2014108-05) 盐城工学院人才引进(No.XJ201719)资助项目
关键词 (R)-3-氨基哌啶 合成 应用 二肽基肽酶Ⅳ抑制剂 (R)-3-aminopiperidine preparation application dipeptidyl peptidase-IV (DPP-IV) inhibitor
  • 相关文献

参考文献3

二级参考文献37

  • 1M. Z. Muldakhmetov,A. M. Gazaliev,I. V. Kirilyus,S. D. Fazylov. Electrolytic synthesis of nipecotic acid ethyl ester[J] 2007,Russian Journal of Applied Chemistry(7):1087~1089
  • 2HIMMELSBACH F, LANGKOPF E, ECKHARDT M, et al. 8- [ 3-amino-piperidin-l-yl ] -xanthines, the production thereof and the use of the same as medicaments: WO, 2004018468 [ P]. 2004 - 03 - 04.
  • 3HAAK T, MEINICKE T, JONES R, et al. Initial combination of linagfiptin and metformin improves glyeaemie control in type 2 di- abetes: a randomized, double-blind, placebo-controlled study [J]. Diabetes ObesMetab, 2012, 14(6): 565 -574.
  • 4SCHEEN A J. Efficacy and safety of Jentadueto (linagfiptin plus metformin) [J]. Exp Opini Drug Safet, 2013, 12(2): 275 - 289.
  • 5KOLIAKI C, DOUPIS J. Linagliptin/Metformin fixed-dose com- bination treatment : a dual attack to type 2 diabetes pathophysiolo- gy[J]. Adv Ther, 2012, 29(12): 993-1004.
  • 6DEL PRATO S, TASKINEN MR, OWENS DR, et al. Efficacy and safety of linagliptln in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three pla- cebo-controlled phase III trials[ J]. J Diabet Complie, 2013, 27 (3) : 274 -279.
  • 7YKI-JARVINEN H, ROSENSTOCK J, I)URAN-GARCIA S, etal. Effects of adding linagliptin to basal insulin regimen for inad- equately controlled type 2 diabetes A 1> 52-week randomized, double-blind study[ J]. Diabetes Care, 2013, 36 (12) : 3875 - 3881.
  • 8HIMMELSBACH F, LANGKOPF E, ECKHARDT M, et al. No- vel 8- ( piperazine-1 -yl ) -and 8 - ( [ 1,4 ] diazepan-1 -yl ) -xanthine, the production and use thereof in the form of a drug: WO, 2005051950 [ P ]. 2005 - 06 - 09.
  • 9PFRENGLE W, PACHUR T, NICOLA T, et al. Method for pro- ducing chiral 8-( 3-amino-piperidin-l-yl )-xanthines: WO, 2006048427 [ P] . 2006 - 05 - 11.
  • 10ECKHARDTM, LANGKOPF E, MARK M, et al. 8-(3-(R)- aminopiperidin-l-yl )-7-but-2-ynyl-3-methyl-l-( 4-methyl-quin- azolin-2-ylmethyl) -3, 7-dihydropurine-2, 6-dione ( BI 1356) , a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes[ J]. J Med Chem, 2007, 50(26): 6450-6453.

共引文献14

同被引文献14

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部